Clinical Trial Search

Primary: Number of Patients With Dose Limiting Toxicities — 0; 1; 1; 1 Participants

Primary: Kaplan-Meier Estimate of PFS by Central Radiological Review: ITT Population — 4.0; 2.8 months — p== 0.07

Primary: Percentage of Sputum Samples Positive for Bacterial Pathogens as Identified by Bacteriological Methods, in Any Stable COPD Patients and During AECOPDs — 74.2; 78; 94.6…

Primary: Pharmacokinetic Parameter of Maximum (Peak) Observed Serum Concentration (Cmax) Following Treatment With DS-8201a and Ritonavir - Cohort 1 — 133; 140; 121; 126 ug/mL

Primary: Number of Sick Days — p=< 0.05

Primary: Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST): Primary Efficacy Population — 14.4; 14.4 Percentage of Patients

Primary: Progression-Free Survival (PFS) at 36-Months for Patients Who Received 4 Cycles of ABVD — .91 proportion of patients

Primary: Percentage of Subjects Achieving at Least 20% Improvement From Baseline in American College of Rheumatology (ACR) Core Set Measures (ACR20 Response Rate) Compared to…

Primary: Systolic Pressure Value — 26.5; 27.75; 16.6; 13.6 millimeters of mercury (mmHg)

Primary: Palpebral Fissure Height — 9.64; 9.66; 9.92; 9.96 milimeter

Primary: Change in Hospital Anxiety and Depression Scale (HADS), Anxiety — -3.9; -5.7; -3.5 score on a scale — p=0.038

Primary: Mean Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control Groups — -0.14 Diopter (D)

Primary: Summary Statistics and Primary Pairwise Comparison (Vehicle-E6201) of Area Under the Curve (AUC) for the Baseline-Corrected Thickness of the Psoriatic Infiltrate…

Primary: Stroke Impact Scale (SIS-16) — 79.9; 80.6 score on a scale

Primary: Overall Summary of the Number of Participants With Adverse Events, Severity Assessed According to the World Health Organization (WHO) Toxicity Grading Scale — 163; 2…